[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638955":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":27,"responsibleParty":72,"collaborators":19,"id":74,"slug":19,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":19,"enrollmentInfo":82,"targetDuration":19,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":19,"overallStatus":91,"whyStopped":19,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"18F-DPA-714 PET radiotracer uptake within the perihematomal edema","EXPERIMENTAL","18F-DPA-714 injection for TEP",[13],"Drug: TEP with 18F-DPA-714 injection",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","TEP with 18F-DPA-714 injection",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Nicolas RAPOSO, MD, PHD","CONTACT","05 61 77 76 40","33","raposo.n@chu-toulouse.fr",[28,45,59],{"facility":29,"status":19,"city":30,"state":19,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"CHU de Bordeaux","Bordeaux","33000","France","FR",{"type":35,"coordinates":36},"Point",[37,38],-0.58046,44.84124,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":25,"email":44},"Igor Sibon, MD, PHD",".5.56.79.55.20","igor.sibon@chu-bordeaux.fr",{"facility":46,"status":19,"city":47,"state":19,"zip":48,"country":32,"countryCode":33,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"CHU de montpellier","Montpellier","34000",{"type":35,"coordinates":50},[51,52],3.87635,43.61093,{"lat":52,"lon":51},[55],{"name":56,"role":23,"phone":57,"phoneExt":25,"email":58},"Adrien Ter Schiphorst, MD",".4.67.33.67.33","adrien.ter.schiphorst@gmail.com",{"facility":60,"status":19,"city":61,"state":19,"zip":62,"country":32,"countryCode":33,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"CHU de Toulouse","Toulouse","31000",{"type":35,"coordinates":64},[65,66],1.44367,43.60426,{"lat":66,"lon":65},[69],{"name":70,"role":23,"phone":71,"phoneExt":25,"email":26},"Nicolas Raposo, MD, PHD","5 61 77 76 40",{"type":73,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100638955",false,"NCT07583147","Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage.","INFINITE","Inclusion Criteria:\n\n1. Adults (≥ 18 years old);\n2. presenting with a symptomatic spontaneous supratentorial ICH;\n3. ICH within 48 hours after symptoms onset (or last seen well);\n4. ICH confirmed by brain imaging;\n5. Informed consent documented;\n6. Affiliated or beneficiary of social security scheme.\n\nExclusion Criteria:\n\n1. Massive ICH volume (≥ 60 ml) at admission;\n2. Severe coma (defined as a Glasgow Coma Scale score \\\u003C 6) at admission;\n3. Planned neurosurgical hematoma evacuation;\n4. Decision already taken for palliative care with withdrawal of active treatment;\n5. Pre-existing dependance defined as a mRS score ≥2 prior to ICH occurrence;\n6. Underlying secondary cause of ICH including macrovascular causes (brain arteriovenous malformation, intracranial aneurysm, dural arteriovenous fistula, cavernous malformation), brain tumour, cerebral venous thrombosis, hemorrhagic infarction. Patients taking oral anticoagulant can be included;\n7. TSPO genotyping demonstrating a low affinity binder profile,\n8. Unable to tolerate or contraindicated to brain MRI: medical material not MRI compatible, claustrophobia, known hypersensitivity to gadoteric acid, meglumin or any drug containing gadolinium;\n9. Estimated glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73 m 2\n10. Unable to tolerate or contraindicated to 18F-DPA714 PET: women who are pregnant or breastfeeding, claustrophobia, and known hypersensitivity to DPA-714;\n11. Use of Benzodiazepines within 7 days (within 6 weeks for prazepam, diazepam or clorazepate) preceding TSPO PET acquisition;\n12. Co-existing neuroinflammatory disease such as Multiple Sclerosis, Neuromyelitis optica, Neurosarcoidosis, autoimmune encephalitis, CNS vasculitis;\n13. Conditions requiring long-term immunosuppressive medication;\n14. Expected impossible follow-up or poor compliance;\n15. Patient under tutorship, curatorship, or legal protection.","ALL","18 Years",{"count":83,"type":84},117,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","In this prospective, multicenter study of patients with acute spontaneous supratentorial Intracerebral Hemorrhage (ICH), each participant will have a standardized multimodal evaluation of neuroinflammation at 10 (±2) days after onset including translocator protein 18 kDa (TSPO) positron emission tomography (PET) using 18F-DPA-714 radioligand, BBB imaging using Dynamic contrast-enhanced (DCE)-MRI and a panel of pro-inflammatory and anti-inflammatory plasma biomarkers.",[90],"Intracerebral Hemorrhage","NOT_YET_RECRUITING","2026-05-06",{"date":94,"type":95},"2026-05-13","ACTUAL",{"date":97,"type":84},"2026-06",{"date":99,"type":84},"2029-12",{"name":5,"class":6},3]